Understanding Human Papillomavirus (HPV) and the need for vaccination.

Maryanne Senna*

Department of Dermatology, Lahey Hospital & Medical Center, UK

Introduction

Human Papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide, affecting both men and women. There are over 100 types of HPV, with at least 14 considered high-risk for leading to cancer. HPV is responsible for nearly all cases of cervical cancer, as well as a significant proportion of anal, penile, throat, and vaginal cancers. The widespread prevalence and potential severity of HPV infections make vaccination a critical public health intervention.The HPV vaccine is designed to protect against the most dangerous strains of the virus, particularly types 16 and 18, which cause around 70% of cervical cancer cases. Other strains, like types 6 and 11, are linked to genital warts and are also included in some vaccines. Currently, vaccines such as Gardasil 9 offer broad protection and are approved for use in both males and females, ideally before the onset [1,2].

Health authorities, including the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), recommend that children receive the HPV vaccine around the ages of 11 to 12, though it can be administered as early as age 9. For individuals who begin the vaccination before their 15th birthday, two doses are usually sufficient. Those starting at age 15 or older generally require three doses for full protection. The goal is to vaccinate individuals before they are exposed to the virus through sexual contact.Extensive research and real-world data have confirmed that the HPV vaccine is safe and highly effective. Clinical trials and long-term follow-ups have shown a significant reduction in HPV infections, genital warts, and cervical precancerous lesions in vaccinated populations. Side effects are generally mild, including soreness at the injection site, headache, or low-grade fever. Serious side effects are extremely rare, and health authorities continue to monitor vaccine safety rigorously. [3,4].

Despite its proven benefits, HPV vaccination coverage varies widely around the world. High-income countries often have robust immunization programs, whereas many low- and middle-income countries face challenges such as limited access, vaccine hesitancy, cultural barriers, and lack of awareness. Addressing these issues is essential to ensure equitable protection against HPV-related diseases. Initially, HPV vaccination campaigns focused primarily on females due to the link between HPV and cervical cancer. However, growing awareness of HPV-related cancers in men has led to the inclusion of boys in vaccination programs. Vaccinating both genders not only provides direct protection but also helps reduce the overall circulation of the virus, contributing to herd immunity and greater public health outcomes.Public health campaigns, school-based vaccination programs, and community outreach play a crucial role in improving vaccine uptake. Educating parents, caregivers, and adolescents about the safety and benefits of the HPV vaccine is key to overcoming misinformation and vaccine hesitancy. Healthcare providers are also instrumental in recommending and administering the vaccine [5,6].

With continued efforts to expand vaccine access and coverage, the global health community is optimistic about significantly reducing, and potentially eliminating, cervical cancer in the future. The HPV vaccine represents a powerful tool in this fight, combining science, policy, and education to protect generations from preventable diseases. [7,8].

Human Papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide, with over 200 known types, of which around 14 are high-risk and associated with the development of various cancers, including cervical, anal, and oropharyngeal cancers. HPV is primarily transmitted through sexual contact, and most infections are asymptomatic and self-limiting. However, persistent infection with high-risk HPV types can lead to cellular changes and malignant transformation, particularly in the cervix. Vaccination against HPV, particularly with the quadrivalent and nonavalent vaccines, has proven highly effective in preventing infections with the most common cancer-causing strains. Routine screening through Pap smears and HPV DNA testing also plays a critical role in early detection and prevention of cervical cancer. Public health initiatives focusing on vaccination, awareness, and regular screening are essential in reducing the global burden of HPV-related diseases.[9,10].

Conclusion

Human Papillomavirus remains a significant global health concern due to its strong association with various cancers, particularly cervical cancer. However, with the availability of effective vaccines, regular screening programs, and increased public awareness, HPV-related complications can be largely prevented. Continued efforts in education, vaccination, and

***Correspondence to:** Maryanne Senna*, Department of Dermatology, Lahey Hospital & Medical Center, UK. Email: MaryanneSenna@lahey.org

***Received:** 01-May-2025, Manuscript No. AAGGS-25-164349; **Editor assigned:** 02-May-2025, Pre QC No. AAGGS-25-164349(PQ); **Reviewed:**15-May-2025, QC No. AAGGS-25-164349; **Revised:**19-May-2025, Manuscript No. AAGGS-25-164349(R), **Published:**28-May-2025, DOI:10.35841/aaggs-9.3.262*

***Citation:** Senna M. Understanding Human Papillomavirus (HPV) and the need for vaccination. Gynecol Reprod Endocrinol. 2025;9(3):262*

early detection are essential to reducing the prevalence of HPV infections and improving long-term health outcomes, especially for women in low- and middle-income countries where cervical cancer rates remain high.

References

1. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Critical Care Med. 2000;162(3):891-5.
2. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. The J Pediatr. 2004;144(2):154-61.
3. Wahabi HA, Fayed AA, Esmaeil SA, et al. Progestogen for treating threatened miscarriage. Cochrane Database of Systematic Rev. 2018(8).
4. Farquar CM. Ectopic pregnancy. Lancet 2005;366(9485):583–91.
5. Dogra V, Paspulati RM, Bhatt S. First trimester bleeding evaluation. Ultrasound Quarterly. 2005;21(2):69-85.
6. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ. 1997;315(7099):32-4.
7. Colpi G, Weidner W, Jungwirth A, et al. EAU guidelines on ejaculatory dysfunction. Eur Urol. 2004;46(5):555–8.
8. Bener A, Al-Ansari AA, Zirie M, et al. Is male fertility associated with type 2 diabetes mellitus?. Int Urol Nephrol. 2009;41(4):777-84.
9. Palmer JS, Kaplan WE. Erectile dysfunction in spina bifida is treatable. The Lancet. 1999;354(9173):125-6.
10. Crich JP, Jequier AM. Infertility in men with retrograde ejaculation: the action of urine on sperm motility, and a simple method for achieving antegrade ejaculation. 1978;30(5):572-6.

Citation: *Senna M. Understanding Human Papillomavirus (HPV) and the need for vaccination. Gynecol Reprod Endocrinol. 2025;9(3):262*